Constantine S Mitsiades

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. request reprint
    Mitsiades C, Kotoula V, Poulaki V, Sozopoulos E, Negri J, Charalambous E, et al. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab. 2006;91:3662-6 pubmed
    ..The presence of EGFR-activating TK domain mutations may identify a small minority of thyroid cancer patients that may benefit from EGFR inhibitors, but additional preclinical evidence of efficacy is needed. ..
  2. Mitsiades C, Mitsiades N, McMullan C, Poulaki V, Kung A, Davies F, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood. 2006;107:1092-100 pubmed
  3. request reprint
    Mitsiades C, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, et al. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab. 2006;91:4013-21 pubmed
  4. request reprint
    Mitsiades C, Negri J, McMullan C, McMillin D, Sozopoulos E, Fanourakis G, et al. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Mol Cancer Ther. 2007;6:1070-8 pubmed
    ..Small molecule inhibitors that selectively target B-Raf(V600E) may provide clinical benefit for patients with thyroid cancer. ..
  5. Mitsiades C. Tight Junction Protein 1: New Insights into Proteasome Inhibitor Resistance and Myeloma Pathophysiology. Cancer Cell. 2016;29:611-612 pubmed publisher
    ..report that TJP1 suppresses EGFR/JAK1/STAT3-mediated signaling and increases the proteasome inhibitor sensitivity of myeloma cells by altering the cellular proteasome capacity versus proteasome load of undegraded intracellular proteins. ..
  6. Dowling P, Hayes C, Ting K, Hameed A, Meiller J, Mitsiades C, et al. Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease. BMC Genomics. 2014;15:904 pubmed publisher
    ..These biomolecules may therefore be clinically useful in assessing the extent of bone disease. ..
  7. request reprint
    Mitsiades C, Hayden P, Kotoula V, McMillin D, McMullan C, Negri J, et al. Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition. J Clin Endocrinol Metab. 2007;92:4845-52 pubmed
  8. Matthews G, de Matos Simoes R, Dhimolea E, Sheffer M, Gandolfi S, Dashevsky O, et al. NF-?B dysregulation in multiple myeloma. Semin Cancer Biol. 2016;39:68-76 pubmed publisher